Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AM 424; Leukaemia inhibitory factor; Leukemia inhibitory factor; LIF; recombinant leukaemia inhibitory factor; Recombinant leukaemia inhibitory factor protein - Ares-Serono; Recombinant LIF protein - Ares-Serono; rhLIF

Latest Information Update: 02 May 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Walter and Eliza Hall Institute of Medical Research
  • Class Cytokines; Neuroprotectants
  • Mechanism of Action Leukaemia inhibitory factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Female infertility; Neuromuscular disorders

Most Recent Events

  • 23 Jun 2004 Data from a media release have been added to the Women's Health therapeutic trials section
  • 04 Jun 2004 Serono has completed the international proof-of-concept phase II trial with emfilermin for female infertility
  • 07 Jul 2003 Data from a media release have been added to the adverse events and Women's health therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top